Abbott LaboratoriesvsFate Therapeutics

ABT and FATE stock compared: price, dividend, valuation and results, from SEC filings.

ABT

Abbott Laboratories

$103.00

Value $179B

-0.84%
ABT's page

FATE

Fate Therapeutics, Inc.

$0.92

Value $107M

-8.91%
FATE's page

Abbott Laboratories (ABT) has a market value of $179B and Fate Therapeutics (FATE) $107M. Over the last year, with dividends, ABT moved -16.3% and FATE -12.4%. Dividend yield: ABT 2.45%, FATE none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABT$179B

    FATE$107M

    ABT is 1,675 times FATE

  • Revenue, 12 months

    ABT$48.2B

    FATE$4.8M

    ABT is 10,153 times FATE

  • Net income, 12 months

    ABT$4.7B

    FATE-$124M

  • Operating margin

    ABT13.8%

    FATE-2,760.0%

    2,773.8 points apart

  • ROIC

    ABT6.3%

    FATE-57.1%

    63.4 points apart

  • P/E

    ABT38.1

    FATE–

  • Dividend yield

    ABT2.5%

    FATE0.0%

    2.5 points apart

  • 5-year return

    ABT-10.3%

    FATE-98.4%

    88.1 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABT-10.3%

FATE-98.4%

05010020222023202420252026
Returns by period
PeriodABTWith dividendsFATEWith dividends
1 year since November 19, 2025-16.3%Price -18.4%-12.4%Price -12.4%
3 years since November 20, 2023+8.4%+2.7% a yearPrice +1.8%-64.6%-29.3% a yearPrice -64.6%
5 years since November 19, 2021-10.3%-2.1% a yearPrice -18.8%-98.4%-56.0% a yearPrice -98.4%
10 years since November 22, 2016+226.2%+12.5% a yearPrice +170.3%-68.7%-11.0% a yearPrice -68.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABTAbbott LaboratoriesFATEFate Therapeutics

Valuation

ABTFATE
Valuation
Price$103.00$0.92
Market value$179B$107M
Enterprise value (EV)$206B–
P/E38.1–
P/E, 5-year median33.7–
P/B3.50.8
EV/EBIT31.0–
Free cash flow yield3.8%–

Results and growth

ABTFATE
Results and growth
Revenue, 12 months$48.2B$4.8M
Net income, 12 months$4.7B-$124M
Free cash flow, 12 months$6.8B-$107M
Earnings per share, 12 months$2.69-$1.03
Revenue growth, year on year5.7%-51.2%
Revenue growth a year, past+5.1%over 5 years-26.7%over 5 years
EPS growth a year, past+8.3%over 5 years–

Margins and returns on capital

ABTFATE
Margins and returns on capital
Gross margin56.9%–
Operating margin13.8%-2,760.0%
Net margin9.8%-2,619.6%
ROIC6.3%-57.1%
ROE9.1%-68.6%

Balance sheet

ABTFATE
Balance sheet
Cash$4.3B$139M
Total debt$31.2B$74M
Net debt / EBITDA3.3–
Interest cover6.7×–

Dividends and buybacks

ABTFATE
Dividends and buybacks
Dividend yield2.5%–
Dividend per share, 12 months$2.52–
Dividend growth a year, past+10.4%over 5 years–
Buyback yield0.5%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABT or FATE

Didn't find what you were looking for?

Ask us
Which is bigger, Abbott Laboratories or Fate Therapeutics?

By market value, Abbott Laboratories ($179B) is about 1,675.1 times Fate Therapeutics ($107M), at today's prices.

How did ABT and FATE stock do over the last 10 years?

Since November 22, 2016, ABT's price moved +170.3% and FATE's -68.7%. With dividends: ABT +226.2% (+12.5% a year), FATE -68.7% (-11.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABT or FATE?

The dividend yield at today's price is 2.45% for Abbott Laboratories and none for Fate Therapeutics. Over the last twelve months they paid $2.52 and – per share.

Which has the higher profit margins, Abbott Laboratories or Fate Therapeutics?

Over the last twelve months, the net margin was 9.8% for Abbott Laboratories and -2,619.6% for Fate Therapeutics, and the operating margin 13.8% and -2,760.0%. Revenue was $48.2B and $4.8M.

Which is the better investment, Abbott Laboratories or Fate Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.